9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

Estimated reading time: < 1 min

Condition: Mesothelioma

Estimated Enrollment: 57

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Objective Response Rate,  Progression Free Survival,  Overall Survival, Number of participants with treatment-related adverse events, as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0

Interventions: Niraparib,

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: December 2021

Completion Date: December 2022

Last  Posted Date: May 2, 2019

Location: University of Florida, Gainesville, Florida, United States

Website Link: https://ClinicalTrials.gov/show/NCT03207347

Was this article helpful?
Dislike 0